The effect of administration of metformin on lipid profile changes and insulin resistance in patients with polycystic ovary syndrome
|
|
- Marilynn Daniella Bailey
- 8 years ago
- Views:
Transcription
1 Middle East Fertility Society Journal Vol. 12, No. 3, 2007 Copyright Middle East Fertility Society The effect of administration of metformin on lipid profile changes and insulin resistance in patients with polycystic ovary syndrome Mohamad Ali Karimzadeh, M.D. * Maryam Eftekhar, M.D. * Robabeh Taheripanah, M.D. Naeimeh Tayebi, M.D. * Leili Sakhavat, M.D. * Fatemeh Zare, M.D. * Clinical and Research Center for Infertility, Shahid Sadoughi University. Yazd, Iran ABSTRACT Objective: Polycystic ovary syndrome (PCOS) is one of the most common metabolism and endocrine disorders among women. The aim of the present study was to evaluate the effects of metformin on lipid profile changes, insulin resistance, body mass index (BMI), Ovulation and pregnancy rates in patients affected by PCO syndrome. Materials and Methods: In this randomized controlled study, 200 women aged years with PCOS were selected. Diagnostic criteria were based on the diagnostic criteria of PCO syndrome in Noterdam meeting in Samples of fasting peripheral blood were taken from all patients to test cholesterol, LDL, HDL, TG, FBS and Insulin before treatment. Patients were then divided randomly into two groups. In case group (n=100), metformin was prescribed three times a day (1500 mg daily) and in control group (n=100), placebo was administered in the same way. After three months, sample of blood was taken again in order to test the variance of the above mentioned parameters to compare with these amounts before test. Also, BMI was compared before and after treatment in both groups. Results: BMI was 28.81±3.18 and ± 4.7 Kg/m2 before treatment in case and control groups respectively. This ratio changed after treatment to ± 2.8 and ± 4.8 Kg/m2 in case and control groups respectively (Pvalue>0.05). FSH/insulin ratio was 4.67±0.9 and 5.03±1.3 in case and control group respectively, while it changed after treatment to 6.07 ± 1.4 and 5.05 ±1.3 and this difference was significant in case group (P-value=0.0001),but it was no difference in control group. In case group, HDL level increased after treatment from 26.65±9.9 to 33.19± 9.9 MMoL/L (P-value=0.0001), and Triglyceride level decreased after treatment from ±58.9 to ±55.4 MMoL/L (P-value=0.004); whereas there was no change in control group. LDL and cholesterol levels did not change in both groups. Ovulation rate and pregnancy rate were significantly higher in case group than in control group (86% vs. 20%) (P-value=0.003) and (40% vs. 11%) (P=0.021) respectively. In addition, Metformin had no significant effect on BMI in case group. Conclusion: Treatment with metformin during 3 months causes not only the increase in ovulation and pregnancy rates but also the decrease in insulin resistance and lipid profile changes. Key words: metformin, PCO syndrome, lipid profile, hyperinsulinemia Polycystic ovary syndrome is one of the most common metabolism and endocrine disorders among women with the prevalence of about %5- %10 worldwide (1).One study investigated its prevalence among girl students in Yazd, Iran and reported the prevalence of %16 (2). * Research and Clinical Center for Infertility, Shahid Sadoughi University of Medical Science, Yazd, Iran. Department of Ob & Gyn, Shaheed Beheshti University of Medical sciences, Tehran, Iran. Correspondence: M. Karimzadeh: makarimzadeh@yahoo.com This disorder affects women in reproductive age. The signs of PCOS include hyperandrogenism and anovulation. Since the cause of this syndrome has not been diagnosed yet, therefore its treatment will be depending on signs and patients characteristics such as: hirsutism, obesity, menstrual disorder and infertility (3). The long term damages such as heart complication, diabetes and endometrial cancer should be considered important in this syndrome. Therefore, many researches lead to investigate the lipid 174 Karimzadeh et al. Metformin and polycystic ovary syndrome MEFSJ
2 changes and metabolic effects in PCO patients (3). PCO patients are resistance to insulin and it is not related to obesity (1), while different studies have shown that insulin has a main role in pathogenesis of this syndrome and has direct effect on ovarian steroidogenesis and consequently, it stimulates the synthesis of androgens in theca cells and reduces steroid hormone binding globulin (SHGC) in liver and increases the level of androgen (4). Some randomized clinical trials indicated that treatment with metformin in PCOS decreased the insulin resistance and corrected lipid metabolism (5, 6, 7). The other studies reported that using this drug in PCO patients reduced serum androgens level and consequently menstrual periods became regular (6, 8,9). Banaszewska et al (2006) have concluded that metformin therapy in hyperinsulinemic women was associated with a significant decrease of insulin level, total cholesterol, LDL and TG that this drug may be considered as a prophylactic therapy lowering cardiovascular risk factors in hyperinsulinemic women with PCOS (10) Our aim is to investigate the effect of metformin on lipid profile changes, insulin resistance and BMI, ovulation and pregnancy rates in PCO patients. MATERIALS AND METHODS A randomized controlled trial was conducted to compare the effect of metformin on lipid profile changes, insulin resistance, BMI, ovulation and pregnancy rates in PCO patients before and after treatment between August 2005 and September Ethical committee of Yazd Shahid Sadughi University of Medical Science approved this study. In total, 200 women (The range of age was years) who have referred to our clinic because of menstrual disorder, hirsutism and infertility were diagnosed with PCOS. PCOS was diagnosed according to its definition in 2003 Noterdam meeting namely by the existence of at least two of the following criteria: oligomenorrhea (the length of period days is more than 35 days) or hypo menorrhea, Clinical signs of hirsutism, hyperandrogenism, and sonographic evidence of PCO (such as ovarian volume>10cm3 and small (6-8mm) follicles more than 12 arranged in the periphery of the ovary). The exclusion criteria were included other endocrinological abnormalities such as hyperprolactinaemia, and thyroid dysfunction, Cushing syndrome, congenital adrenal hyperplasia. BMI was measured and recorded in all patients before and after treatment. The sample of fasting peripheral blood was taken in order to measure cholesterol, HDL, LDL, triglyceride, FBS and fasting insulin. Then patients were randomly (Randomization was performed using computergenerated sequences that were sealed in number opaque envelopes) divided into two groups. Metformin was prescribed for case group (n=100) and placebo for control group (n=100). Both women and the doctor were blinded to the content of tablet which had identical appearance and were packaged by the clinic pharmacist. The dose of metformin was started from one tablet 500 mg /day and increased to three tablets daily during a week with respect to the patient s tolerance. Placebo was prescribed for control group in the same method. After three months, the sample of blood peripheral was taken again in order to check the mentioned parameters. Then the data was compared with these amounts before treatment. All patients were asked to report all the side effects such as nausea, vomiting and diarrhea during the treatment. Ovulation rates were determined by progesterone levels of more than 10ng/ml in the luteal phase (timed 21 days after the first spontaneous menstruation) for both groups. Pregnancy outcomes included serum B-HCG of more than 50IU/L, and fetal heart activity on abdominal ultrasound scan, after 8 weeks of gestation. SSPS version 13 was used to do the appropriate statistical tests including Student's T Test (twotailed), Fisher exact test. The results are expressed as means and standard deviation. Differences were considered to be statistically significant if p-value was <0.05. RESULTS In this study, 200 PCO patients were recruited during 1 year. 100patients were in the metformin group and 100 in the placebo group. The mean age of patients was 27.2±6.8 and 28.6±7.4 years in case Vol. 12, No. 3, 2007 Karimzadeh et al. Metformin and polycystic ovary syndrome 175
3 Table 1. The mean level of Serum FBS, Cholesterol, LDL, HDL and Triglyceride in both groups. Variable Case Control Pre-treatment Post-treatment P-value Pre-treatment Post-treatment P-value * FBS/Insulin 4.67± ± ± ± Cholesterol ± ± ± ± (mmol/l) Cholesterol 26.65± ± ± ± HDL(mmol/L) Cholesterol ± ± ± ± LDL(mmol/L) Triglyceride (mmol/l) ± ± ± ± * Data were analyzed by paired T Test The results are expressed as means and standard deviation. Differences were considered to be statistically significant if p-value was <0.05. and control group respectively (P-value= 0.42).Duration of infertility was 5.6±1.9 and 6,2±1.8years in case and control groups respectively( P-value= 0.28). Before treatment, the patients with oligomenorrhea were 82% and 75% in case and control groups respectively (Pvalue=0.31), While it was 23% and 70 % in case and control groups after treatment (Pvalue=0.003). Hirsutism was 86% and 82% in case and control groups (P-value=0.51), while it was 50% and 70 % in case and control groups after treatment (P-value=0.07). Before the treatment, the BMI was 28.8±3.18 and 29.49±4.75Kg/m2 in case and control groups respectively (P-value=0.15).After treatment; it was 28.45±2.8 and 29.29±4.8 in case and control groups (P-value=0.18). The degree of the sensitivity to insulin was 4.67±0.9 in case group and 5.03±1.3 in control group. After treatment, the sensitivity to insulin increased significantly to 6.07±1.4 in case and 5.05±1.3 in control group (P-value =0.0001); while it was not significant in control group (P value =0.77) (Table1). As it is shown in table 1, although the amount of cholesterol reduced from ±47.2 to ±58.5 in case group, this reduction was not significant statistically (p=0.069); while no change was seen in control group (199.4±42.5 vs ±42.5). In addition, triglyceride level reduced from ±58.4 to ±55.9 in case group (p=0.004), while it did not reduce in control group (196.56±54.3 vs ±53.4) (p =0.063). Similarly, HDL level increased from 26.65±9.9 to 33.19±9.9 after metformin treatment (Pvalue=0.0001), while this change was not seen in control group. Finally, LDL level was not changed in both groups. Ovulation rate was significantly higher in case group than in control group (86% vs. 20%) (Pvalue=0.003). Also, clinical pregnancy rate was significantly more in case group than in control group (40% vs. 11%) (P=0.021). Four pregnancies in case group and three in group B ended with miscarriage at 8 weeks of gestational age (Pvalue=0.092) In addition, Metformin had no significant effect on BMI in case group. Side effects in metformin treatment were 30% nausea, 10% diarrhea and 15% vomiting. These side effects were not severe and they were disappeared with continuing treatment. DISCUSSION Hyperinsulinemia and hyperandrogenism increase the risk of diabetes in PCO patients (1). In addition, hyperinsulinemia causes hypertension and increases the risk of ischemic heart disease (IHD) in these patients (11). The other risk factor of IHD is insulin resistance which is accompanied with increasing of triglyceride and reduction of HDL level (11). Women with anovulation, hyperandrogenism and hyperinsulinemia are more exposed to the risk of diabetes mellitus independent from insulin (1). 176 Karimzadeh et al. Metformin and polycystic ovary syndrome MEFSJ
4 Different studies have shown that continuous anovulation made the patients three times more susceptible to endometrial cancer (12). On the other hand, the risk of breast cancer increases in patients with chronic anovulation three or four times (1). Metformin increases the sensitivity to insulin that decreases the chance of diabetes (13-15). This drug is available in the market for treatment of diabetes more than 10 years. In fact, it is the most prescribed medicine for the treatment of hyperglycemia. The primary effect of metformin is a significant reduction in gluconeogenesis. Not only decreases glucose production but also increases target tissue sensitivity to insulin. Metformin has useful effects in reduction of the cardiovascular risk factors and it is the early available medication against hyperglycemia which decreases macrovascular complications in diabetic patients (16). It was shown that treatment with 1500 mg of metformin for 8 weeks decreases the level of serum insulin (8, 17). Our results showed that sensitivity to insulin (FBS/insulin ratio) has increased in the case group compared to the control group. Although, the rise of androgen and consequently the lipid changes in PCO patients cause to protect against osteoporosis but its bad effect on heart disease is very important (16). Atherosclerosis is more common among women who have anovulation and PCOD. Cheang and et al (2004) showed that metformin not only recommended for PCO patients because of its effect on induction ovulation, but also for its useful influence on lipid metabolism (18). Our results showed that treatment with metformin caused a significant increase in HDL and a decrease in triglyceride level. However, although cholesterol and LDL serum levels decreased after treatment with metformin, it was no significant difference between before and after treatment in case group. Therefore, treatment with metformin may cause the prevention of long term risk of cardiovascular and diabetes through correcting all or some of risk factors and lipid profile changes (19). Tang and co-workers (2006) have indicated that there were no significant changes in insulin sensitivity or lipid profiles after treatment with metformin. Also, in this study, metformin did not improve weight loss or menstrual frequency in patients with PCOS (20). The effect of metformin has been controversial; with some suggestion that the ovulatory response is the result of the weight loss that often accompanies its use. In a study designed to control the effect of body weight, the administration of metformin was without effect on insulin resistance in extremely overweight women with polycystic ovaries (21). In another-well designed study, metformin again had no effect on insulin resistance when body weights remained unchanged, and baseline weights and hyperinsulinemia were only modestly increased (22). In contrast to some of the studies that metformin has a good effect on the reduction of weight and BMI (23, 24), our investigation showed that there was no significant difference in weight and BMI after treatment with metformin. Santana et al (2004) have shown that treatment with metformin increased HDL level while serum total cholesterol and LDL levels reduced. Also, there were no changes in BMI after metformin treatment (25). Aruna s study (2004) indicated that significant improvement menstrual cyclicity, ovulation and pregnancy rates were noted after treatment with metformin (26).Our results were the same as this study. However, Treatment with metformin will decrease insulin resistance and lipid profile changes and increase ovulation and pregnancy rates. REFERENCES 1. Leon Speroff. Clinical Gynecologic endocrinology and infertility- lippincott Williams 2005, 12: Aghili T, Karimzade M.A. Epidemiological aspects of Polycystic ovarian syndrome in students of Shahid Sadoughi University, Thesis for Gynecology specialist, Shahid Sadoughi University of Medical science, Yazd, Iran, Ajossa S, Guerriero S, Paoletti AM, Orru M, Melis GB. The treatment of poly cystic ovary syndrome. Minerva Gynecol. 2004, 56: Dunaif A. Insulin resistance and ovarian hyperandrogenism. Endocrynologist. 1992, 2: Awartani KA, Cheung AP. Metformin and polycystic ovary syndrome: a literature review. J Obstet Gynaecol. 2002, 24: Glueck CJ, Panna R, wang P, Goldenberg N, Sieve-Smith L. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovary syndrome. Metabolism.2003, 52: Velazquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ. Vol. 12, No. 3, 2007 Karimzadeh et al. Metformin and polycystic ovary syndrome 177
5 Metformin therapy in polycystic ovary syndrome reduced hyperinsulinemia hyperandrogenism and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism. 1994, 43: De leo V, La Marca A, Diffo A. Effect of metformin on gonadotropin induced ovulation in women with poly cystic ovary syndrome. Fertil Steril. 1999, 72: Paapunen M. Metformin therapy in polycystic ovary syndrome. Metabolism 1998, 40: Banaszewska B, Duleba AJ, Spaczynski RZ, Pawelczyk L. Lipids in polycystic ovary syndrome: role of hyperinsulinemia and effects of metformin. Am J Obstet Gynecol. 2006; 194: Santana Lf, desa MF, ferriani RA. Effect of metformin on the clinical and metabolic assessment of women with polycystic ovary syndrome. Gynecol endocrinol.2004, 19: Chou KH, Von eye corleta H, Capp E, Spritzer PM. Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome ;a randomized,double blind and placebo-controlled trial. Hom metab res.2003,35: Moghetti p, Castello R, Negri C, Oosi F, Perrone F, Caputo M, Zanolin E, Muggeo M. Metformin effect on clinical features endocrine and metabolism profile, and insulin sensitivity in polycystic ovary syndrome. J Clin Endocrinol Metab. 2000, 85; Cheang KL, Nestler JE. Should insulin-sensitizing drugs be used in treatment of polycystic ovary syndrome? Reprod Biomed Oonline.2004, 8: Hunadal RS. Metformin: new understanding, new uses drug.2003, 63: Morin-papunen LC, Koivunen RM, Ruokonen A, Martikainen HK. Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women's with polycystic ovary syndrome. fertile steril.1998, 69: Awartanik I, Chiung AP. Metformin and polycystic ovary syndrome; a literature review. J Obstet gynecol.2002, 24: Cheang KI, Nestler JE. Should insulin sensitizing drugs be used in the treatment of poly cystic ovary syndrome? Reprod Biomed Online. 2004, 8: Glueck CJ,Fontaine RN, Wang P. Metformin reduces weight,central obesity,insulin,leptin and low density lipoprotein cholesterol in non diabetic,morbidly obese subjects with body mass index greater than 30. Metabolism. 2001, 50: Tang T, Glanville J, Hayden CJ, White D, Barth JH, Balen AH. Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicenter study. Hum Reprod. 2006; 21: Ehrmann DA, Cavaghan MK, Imperial J, Sturis J, Rosenfield RL, Polosky ks. Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab.1997,82: Acbay O, Gundogdu S. Can metformin reduce insulin resistance in polycystic ovary syndrome? Fertil Steril.1996, 65: Kolodziejczyk B, Duleba AJ, Spaczynski RZ, Pawelczyk L. Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome. Fertil Steril. 2000; 73: Kazerooni T, Dehghan-Kooshkghazi M. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome. Gynecol Endocrinol. 2003; 17: Santana LF,de Sa MF, Ferriani RA, de Moura MD, Foss MC, dos Reis RM. Effect of metformin on the clinical and metabolic assessment of women with polycystic ovary syndrome. Gynecol Endocrinol. 2004; 19: Aruna J, Mittal S, Kumar S, Misra R, Dadhwal V, Vimala N. Metformin in women with polycystic ovary syndrome. Int J Gynaecol Obstet. 2004; 87: Received on January 27, 2007; revised and accepted on May 30, Karimzadeh et al. Metformin and polycystic ovary syndrome MEFSJ
INSULIN RESISTANCE, POLYCYSTIC OVARIAN SYNDROME
1 University of Papua New Guinea School of Medicine and Health Sciences Division of Basic Medical Sciences Discipline of Biochemistry and Molecular Biology PBL SEMINAR INSULIN RESISTANCE, POLYCYSTIC OVARIAN
More informationHEALTH UPDATE. Polycystic Ovary Syndrome (PCOS)
HEALTH UPDATE PO Box 800760 Charlottesville, VA 22908 Gynecology: (434) 924-2773 Polycystic Ovary Syndrome (PCOS) What is it? An endocrine (hormonal) disorder. Because there is such variability in how
More informationPCOS. What to do about insulin resistance in. Aclearer understanding of. In this article: By R. Hugh Gorwill, MD, FRCSC
Focus on CME at Queen s University Queen s University What to do about insulin resistance in PCOS By R. Hugh Gorwill, MD, FRCSC In this article: Aclearer understanding of polycystic ovary syndrome (PCOS)
More informationPOLYCYSTIC OVARY SYNDROME
POLYCYSTIC OVARY SYNDROME Information Leaflet Your Health. Our Priority. Page 2 of 6 What is polycystic ovary syndrome? (PCOS) Polycystic ovary syndrome (PCOS) is the most common hormonal disorder in women
More informationEFFECT OF INCREASED TESTOSTERONE LEVEL ON WOMAN S FERTILITY
1 Nada Polyclinic, Po ega, Croatia 2 School of Medicine, University of Zagreb, Zagreb, Croatia Preliminary Communication Received: April 15, 2004 Accepted: June 16, 2004 EFFECT OF INCREASED TESTOSTERONE
More informationIs Insulin Effecting Your Weight Loss and Your Health?
Is Insulin Effecting Your Weight Loss and Your Health? Teressa Alexander, M.D., FACOG Women s Healthcare Associates www.rushcopley.com/whca 630-978-6886 Obesity is Epidemic in the US 2/3rds of U.S. adults
More informationPolycystic Ovarian Syndrome
Polycystic Ovarian Syndrome What is Polycystic Ovarian Syndrome? Polycystic ovary syndrome (or PCOS) is a common condition affecting 3 to 5% of women of reproductive age. It is linked with hormonal imbalances,
More informationPolycystic Ovary Syndrome
Polycystic Ovary Syndrome Polycystic ovary syndrome (PCOS) is a disorder that affects as many as 5 10% of women. PCOS has three key features: 1) high levels of hormones called androgens; 2) irregular menstrual
More informationPOLYCYSTIC OVARY SYNDROME (PCOS), INSULIN RESISTANCE (IR), & METFORMIN: LATEST DEVELOPMENTS
POLYCYSTIC OVARY SYNDROME (PCOS), INSULIN RESISTANCE (IR), & METFORMIN: LATEST DEVELOPMENTS I. Lane Wong, M.D., F.A.C.O.G. Board Certified, Reproductive Endocrinology and Infertility Recently, there has
More informationPolycystic Ovarian Syndrome (PCOS)
UW MEDICINE PATIENT EDUCATION Polycystic Ovarian Syndrome (PCOS) Signs, symptoms, and treatments What is PCOS? Polycystic ovarian syndrome (PCOS) is a disorder that affects up to 1 in 10 women of reproductive
More informationPolycystic ovary syndrome: what it means for your long-term health
Polycystic ovary syndrome: what it means for your long-term health Information for you Published in February 2005, minor amendments in June 2005 Revised 2009 What is polycystic ovary syndrome? Polycystic
More informationPage 1 of 7 Polycystic Ovary Syndrome (PCOS), Insulin Resistance (IR), & the Metabolic Syndrome
Page 1 of 7 Polycystic Ovary Syndrome (PCOS), Insulin Resistance (IR), & the Metabolic Syndrome I. LANE WONG, MD, FACOG. www.hopeivf.com www.hopefertilitycenter.com Polycystic Ovary Syndrome (PCOS), Insulin
More informationWHAT DOES DYSMETABOLIC SYNDROME MEAN?
! WHAT DOES DYSMETABOLIC SYNDROME MEAN? Dysmetabolic syndrome (also referred to as syndrome X, insulin resistance syndrome, and metabolic syndrome ) is a condition in which a group of risk factors for
More informationSubject Index. Bariatric surgery, obesity management 134
Subject Index Acromegaly, PCOS differential diagnosis 149, 150, 154, 155 Adipokines, see specific adipokines Adiponectin, metabolic syndrome role 41 43 Adolescents, PCOS diagnosis 16, 17 Adrenal hyperplasia,
More informationPolycystic Ovary Syndrome: Diagnosis and Treatment
The American Journal of Medicine (2007) 120, 128-132 UPDATE IN OFFICE MANAGEMENT Polycystic Ovary Syndrome: Diagnosis and Treatment Tracy L. Setji, MD, Ann J. Brown, MD, MHS Department of Medicine, Division
More informationInsulin Resistance and PCOS: A not uncommon reproductive disorder
Insulin Resistance and PCOS: A not uncommon reproductive disorder Joyce L. Ross, MSN, CRNP, CS, FNLA, FPCNA Diplomate Accrediation Council for Clinical Lipidology President Preventive Cardiovascular Nurses
More informationStrategies and the Nursing Care Management of Adolescents Diagnosed with PCOS. Conflicts of Interest. Objectives. None Phaedra Thomas 4/23/2015
Strategies and the Nursing Care Management of Adolescents Diagnosed with PCOS Phaedra Thomas, RN BSN Co-Director and Nurse Educator Center for Young Women s Health Boston Children s Hospital youngwomenshealth.org
More informationINFERTILITY/POLYCYSTIC OVARIAN SYNDROME. Ovulatory Dysfunction: Polycystic ovarian syndrome (PCOS)
Introduction Infertility is defined as the absence of pregnancy following 12 months of unprotected intercourse. Infertility may be caused by Ovulatory Dysfunction, Blocked Fallopian Tubes, Male Factor
More informationPage 1 of 7 Polycystic Ovary Syndrome (PCOS), Insulin Resistance (IR), & the Metabolic Syndrome
Page 1 of 7 Polycystic Ovary Syndrome (PCOS), Insulin Resistance (IR), & the Metabolic Syndrome I. LANE WONG, MD, FACOG. www.hopeivf.com Polycystic Ovary Syndrome (PCOS), Insulin Resistance (IR), Type
More informationPolycystic ovary syndrome (PCOS)
Centre for Diabetes and Endocrinology - Patient information Polycystic ovary syndrome (PCOS) Approximately 1 in 5 women have polycystic ovaries. This describes the appearance of the ovaries when they are
More informationRole of Body Weight Reduction in Obesity-Associated Co-Morbidities
Obesity Role of Body Weight Reduction in JMAJ 48(1): 47 1, 2 Hideaki BUJO Professor, Department of Genome Research and Clinical Application (M6) Graduate School of Medicine, Chiba University Abstract:
More information1. PATHOPHYSIOLOGY OF METABOLIC SYNDROME
1. PATHOPHYSIOLOGY OF METABOLIC SYNDROME Izet Aganović, Tina Dušek Department of Internal Medicine, Division of Endocrinology, University Hospital Center Zagreb, Croatia 1 Introduction The metabolic syndrome
More informationSaudi Med J 2007; Vol. 28 (7): 1039-1043
Free testosterone, luteinizing hormone/follicle stimulating hormone ratio and pelvic sonography in relation to skin manifestations in patients with polycystic ovary syndrome Khalifa E. Sharquie, MD, PhD,
More informationTreating Patients with PRE-DIABETES David Doriguzzi, PA-C First Valley Medical Group. Learning Objectives. Background. CAPA 2015 Annual Conference
Treating Patients with PRE-DIABETES David Doriguzzi, PA-C First Valley Medical Group Learning Objectives To accurately make the diagnosis of pre-diabetes/metabolic syndrome To understand the prevalence
More informationDIABETES YOUR GUIDE TO
YOUR GUIDE TO DIABETES b What is diabetes? b Type 2 diabetes prevention b Prevention checklist b Living with diabetes b Complications b Terms to know b Resources To promote and protect the health of Canadians
More informationTYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION. Robert Dobbins, M.D. Ph.D.
TYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION Robert Dobbins, M.D. Ph.D. Learning Objectives Recognize current trends in the prevalence of type 2 diabetes. Learn differences between type 1 and type
More informationAbigail R. Proffer, M.D. October 4, 2013
Abigail R. Proffer, M.D. October 4, 2013 Topics Human Papillomavirus (HPV) Vaccines Pap smears Colposcopy Contraception Polycystic Ovary Syndrome (PCOS) Can I get pregnant? Miscarriage Abnormal Uterine
More informationPrevention of and the Screening for Diabetes Part I Insulin Resistance By James L. Holly, MD Your Life Your Health The Examiner January 19, 2012
Prevention of and the Screening for Diabetes Part I Insulin Resistance By James L. Holly, MD Your Life Your Health The Examiner January 19, 2012 In 2002, SETMA began a relationship with Joslin Diabetes
More informationCauses, incidence, and risk factors
Causes, incidence, and risk factors Insulin is a hormone produced by the pancreas to control blood sugar. Diabetes can be caused by too little insulin, resistance to insulin, or both. To understand diabetes,
More informationTYPE 2 DIABETES IN CHILDREN DIAGNOSIS AND THERAPY. Ines Guttmann- Bauman MD Clinical Associate Professor, Division of Pediatric Endocrinology, OHSU
TYPE 2 DIABETES IN CHILDREN DIAGNOSIS AND THERAPY Ines Guttmann- Bauman MD Clinical Associate Professor, Division of Pediatric Endocrinology, OHSU Objectives: 1. To discuss epidemiology and presentation
More informationFrom Menses to Menopause: How Hormones Can Affect Blood Glucose Levels. Christine Day, RN, MS, CNS-BC Lake Superior College
From Menses to Menopause: How Hormones Can Affect Blood Glucose Levels Christine Day, RN, MS, CNS-BC Lake Superior College Overview Will review hormonal changes over the female lifespan Discuss the effects
More informationPolycystic Ovarian Disease: Treatment Protocols
October 08, 2011 By Galal Lotfi, MD, MRCOG [1] Stein and Leventhal were the first to recognize an association between the presence of polycystic ovaries and signs of hirsutism, amenorrhea, oligomenorrhea
More informationInsulin is a hormone produced by the pancreas to control blood sugar. Diabetes can be caused by too little insulin, resistance to insulin, or both.
Diabetes Definition Diabetes is a chronic (lifelong) disease marked by high levels of sugar in the blood. Causes Insulin is a hormone produced by the pancreas to control blood sugar. Diabetes can be caused
More informationPOSTMENOPAUSAL HYPERANDROGENEMIA (ANDROID OBESITY, INSULIN RESISTANCE, DIABETES MELLITUS) AND THERAPEUTIC CONSEQUENCES
MENOPAUSE ANDROPAUSE Postmenopausal Hyperandrogenemia 159 POSTMENOPAUSAL HYPERANDROGENEMIA (ANDROID OBESITY, INSULIN RESISTANCE, DIABETES MELLITUS) AND THERAPEUTIC CONSEQUENCES D. FOTH, TH. RÖMER POSTMENOPAUSAL
More informationGetting Off the Chronic Disease Merry-Go-Round: What s the Weight of the Research?
Getting Off the Chronic Disease Merry-Go-Round: What s the Weight of the Research? Jody Dushay, MD MMSc Beth Israel Deaconess Medical Center Boston, MA Session 445 No disclosures Disclosure Jody Dushay,
More informationThe PCOS - Diabetes Connection
PCOS Awareness Symposium 2015 Philadelphia Saturday, April 18 th, 2015 The PCOS - Diabetes Connection Preventing Stroke, Kidney Disease, Liver Disease & Other Complications Katherine Sherif, MD Professor
More informationType 2 Diabetes Mellitus and Insulin resistance syndrome in Children
Type 2 Diabetes Mellitus and Insulin resistance syndrome in Children Anil R Kumar MD Pediatric Endocrinology MCV/VCU, Richmond VA Introduction Type 2 diabetes mellitus (T2 DM) has increased in children
More informationNutrition. Type 2 Diabetes: A Growing Challenge in the Healthcare Setting NAME OF STUDENT
1 Nutrition Type 2 Diabetes: A Growing Challenge in the Healthcare Setting NAME OF STUDENT 2 Type 2 Diabetes: A Growing Challenge in the Healthcare Setting Introduction and background of type 2 diabetes:
More informationOvarian Cyst. Homoeopathy Clinic. Introduction. Types of Ovarian Cysts. Contents. Case Reports. 21 August 2002
Case Reports 21 August 2002 Ovarian Cyst Homoeopathy Clinic Check Yourself If you have any of the following symptoms call your doctor. Sense of fullness or pressure or a dull ache in the abdomen Pain during
More informationCardiovascular Disease Risk Factors Part XII Insulin Resistance By James L. Holly, MD Your Life Your Health The Examiner September 15, 2005
Cardiovascular Disease Risk Factors Part XII By James L. Holly, MD Your Life Your Health The Examiner September 15, 2005 As we approach the end of our extended series on cardiovascular disease risk factors,
More information4/4/2013. Mike Rizo, Pharm D, MBA, ABAAHP THE PHARMACIST OF THE FUTURE? METABOLIC SYNDROME AN INTEGRATIVE APPROACH
METABOLIC SYNDROME AN INTEGRATIVE APPROACH AN OPPORTUNITY FOR PHARMACISTS TO MAKE A DIFFERENCE Mike Rizo, Pharm D, MBA, ABAAHP THE EVOLUTION OF THE PHARMACIST 1920s 1960s 2000s THE PHARMACIST OF THE FUTURE?
More informationFACT SHEET. The Polycystic Ovary Syndrome (PCOS) Introduction
FACT SHEET The Polycystic Ovary Syndrome (PCOS) Introduction The polycystic ovary syndrome (PCOS) is the commonest hormonal disturbance to affect women. The main problems that women with PCOS experience
More informationStatistics of Type 2 Diabetes
Statistics of Type 2 Diabetes Of the 17 million Americans with diabetes, 90 percent to 95 percent have type 2 diabetes. Of these, half are unaware they have the disease. People with type 2 diabetes often
More informationEmmett F. Branigan, MD,* Antoinette Estes, BS, Kenneth Walker, BS, Jillian Rothgeb, BS. Bellingham IVF and Infertility Center, Bellingham, WA
American Journal of Obstetrics and Gynecology (2006) 194, 1696 701 www.ajog.org Thorough sonographic oocyte retrieval during in vitro fertilization produces results similar to ovarian wedge resection in
More informationMetabolic Syndrome Overview: Easy Living, Bitter Harvest. Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007
Metabolic Syndrome Overview: Easy Living, Bitter Harvest Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007 Evolution of Metabolic Syndrome 1923: Kylin describes clustering
More informationThe Journal of Integrated Health Sciences
JIHS Available online at www.jihs.in The Journal of Integrated Health Sciences A study of endocrine profile in premenopausal women with hirsutism Lakhani Som J 1*, Lakhani Om J 2, Raval RC 3 1 Assistant
More informationIncidence of gestational diabetes mellitus in pregnant women
Iranian Journal of Reproductive Medicine Vol.8. No.. pp: 24-28, Winter 200 Incidence of gestational diabetes mellitus in pregnant women Sedigheh Soheilykhah M.D. Mahdie Mogibian 2 M.D., Sodabeh Rahimi-Saghand
More information嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯
The Clinical Efficacy and Safety of Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors in Adults with Type 2 Diabetes Mellitus 嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯 Diabetes Mellitus : A group of diseases characterized
More informationACADEMIC APPOINTMENTS: 2009 to present - Assistant Professor of Mother and Child Health at Qazvin University of Medical Science
CURRICULUM VITAE Name: Sonia Oveisi Address: Qazvin University of Medical Science Qazvin- Iran Tel : 0281-3338034 Date of birth: 7 th Sep. 1971 Email: Soniaoveisi@yahoo.com soveisi@razi.tums.ac.ir EDUCATION:
More informationImprovement in diagnostic performance of the revised total testosterone measuring system in Japanese women with polycystic ovary syndrome
65 ORIGINAL Improvement in diagnostic performance of the revised total testosterone measuring system in Japanese women with polycystic ovary syndrome Hirobumi Niki, Toshiya Matsuzaki, Riyo Kinouchi, Takeshi
More informationThe first endoscopically-delivered device therapy for obese patients with type 2 diabetes
DIABETES WEIGHT ENDOBARRIER THERAPY The first endoscopically-delivered device therapy for obese patients with type 2 diabetes Restore the metabolic health of your patients with EndoBarrier Therapy. Dual
More informationImproving cardiometabolic health in Major Mental Illness
Improving cardiometabolic health in Major Mental Illness Dr. Adrian Heald Consultant in Endocrinology and Diabetes Leighton Hospital, Crewe and Macclesfield Research Fellow, Manchester University Metabolic
More informationClinical Study Comparison of Endocrine Profile and In Vitro Fertilization Outcome in Patients with PCOS, Ovulatory PCO, or Normal Ovaries
International Endocrinology Volume 2012, Article ID 492803, 6 pages doi:10.1155/2012/492803 Clinical Study Comparison of Endocrine Profile and In Vitro Fertilization Outcome in Patients with PCOS, Ovulatory
More informationDiabetes mellitus. Lecture Outline
Diabetes mellitus Lecture Outline I. Diagnosis II. Epidemiology III. Causes of diabetes IV. Health Problems and Diabetes V. Treating Diabetes VI. Physical activity and diabetes 1 Diabetes Disorder characterized
More informationBody Mass Index and Gonadotropin Hormones (LH & FSH) Associate With Clinical Symptoms Among Women With Polycystic Ovary Syndrome
Global Journal of Health Science; Vol. 7, No. 2; 2015 ISSN 1916-9736 E-ISSN 1916-9744 Published by Canadian Center of Science and Education Body Mass Index and Gonadotropin Hormones (LH & FSH) Associate
More informationMENOPAUSE WOMAN'S TEST (Assessment of hormone balance)
ATTACHMENT: Useful remarks for patient and doctor, to be associated to the analytical results. Your doctor should interpret this report. Cod. ID: 123456 CCV: 6bf Date: 01/01/2013 Patient: Rossi Mario Rapport
More informationAm I at Risk for type 2 Diabetes? Taking Steps to Lower the Risk of Getting Diabetes NATIONAL DIABETES INFORMATION CLEARINGHOUSE
NATIONAL DIABETES INFORMATION CLEARINGHOUSE Am I at Risk for type 2 Diabetes? Taking Steps to Lower the Risk of Getting Diabetes U.S. Department of Health and Human Services National Institutes of Health
More informationDiagnosis and treatment of polycystic ovary syndrome (PCOS): An interview with Richard Legro
Legro BMC Medicine (2015) 13:64 DOI 10.1186/s12916-015-0299-2 QUESTION AND ANSWER Diagnosis and treatment of polycystic ovary syndrome (PCOS): An interview with Richard Legro Richard Legro Open Access
More informationMarkham Stouffville Hospital
Markham Stouffville Hospital Adult Diabetes Education Frequently Asked Questions What is diabetes? Diabetes is a disease in which blood glucose levels are above normal. Most of the food we eat is turned
More informationPowerPoint Lecture Outlines prepared by Dr. Lana Zinger, QCC CUNY. 12a. FOCUS ON Your Risk for Diabetes. Copyright 2011 Pearson Education, Inc.
PowerPoint Lecture Outlines prepared by Dr. Lana Zinger, QCC CUNY 12a FOCUS ON Your Risk for Diabetes Your Risk for Diabetes! Since 1980,Diabetes has increased by 50 %. Diabetes has increased by 70 percent
More informationClinical Research on Lifestyle Interventions to Treat Obesity and Asthma in Primary Care Jun Ma, M.D., Ph.D.
Clinical Research on Lifestyle Interventions to Treat Obesity and Asthma in Primary Care Jun Ma, M.D., Ph.D. Associate Investigator Palo Alto Medical Foundation Research Institute Consulting Assistant
More informationSponsor. Novartis Generic Drug Name. Vildagliptin. Therapeutic Area of Trial. Type 2 diabetes. Approved Indication. Investigational.
Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Investigational Study Number CLAF237A2386 Title A single-center,
More informationEndocrine issues in FA SUSAN R. ROSE CINCINNATI CHILDREN S HOSPITAL MEDICAL CENTER
Endocrine issues in FA SUSAN R. ROSE CINCINNATI CHILDREN S HOSPITAL MEDICAL CENTER 80% of children and adults with FA have an endocrine abnormality Endocrine cells make a hormone (message) Carried in bloodstream
More informationDiabetes Complications
Managing Diabetes: It s s Not Easy But It s s Worth It Presenter Disclosures W. Lee Ball, Jr., OD, FAAO (1) The following personal financial relationships with commercial interests relevant to this presentation
More informationAging Well - Part V. Hormone Modulation -- Growth Hormone and Testosterone
Aging Well - Part V Hormone Modulation -- Growth Hormone and Testosterone By: James L. Holly, MD (The Your Life Your Health article published in the December 4th Examiner was a first draft. It was sent
More informationAssociation of body mass index, age, and cigarette smoking with serum testosterone levels in cycling women undergoing in vitro fertilization
Association of body mass index, age, and cigarette smoking with serum testosterone levels in cycling women undergoing in vitro fertilization Robert L. Barbieri, M.D., a Pat M. Sluss, M.D., b Robert D.
More informationMY TYPE 2 DIABETES NUMBERS
BLOOD SUGAR MANAGEMENT GUIDE MY TYPE 2 DIABETES NUMBERS Understanding and Tracking the ABCs of Type 2 Diabetes 1 BLOOD MY TYPE SUGAR 2 DIABETES MANAGEMENT ABC NUMBERS GUIDE When you have type 2 diabetes,
More informationPublished Quarterly Mangalore, South India ISSN 0972-5997 Volume 4, Issue 1; January-March 2005
Published Quarterly Mangalore, South India ISSN 0972-5997 Volume 4, Issue 1; January-March 2005 Original Article Genetic Association Between Insulin Resistance And Total Cholesterol In Type 2 Diabetes
More informationPlasma Testosterone Level in Male Patients with Metabolic Syndrome
Med. J. Cairo Univ., Vol. 77, No. 1, June: 351-357, 2009 www.medicaljournalofcairouniversity.com Plasma Testosterone Level in Male Patients with Metabolic Syndrome NASHWA EL-SARRAF, M.D. and AMR EL-HADIDY,
More informationDiabetes and Heart Disease
Diabetes and Heart Disease Diabetes and Heart Disease According to the American Heart Association, diabetes is one of the six major risk factors of cardiovascular disease. Affecting more than 7% of the
More informationGuidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes
Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes U.S. Department of Health and Human Services Food and Drug Administration Center
More informationDiagnosis, classification and prevention of diabetes
Diagnosis, classification and prevention of diabetes Section 1 1 of 4 Curriculum Module II 1 Diagnosis, classification and presentation of diabetes Slide 2 of 48 Polyurea Definition of diabetes Slide 3
More informationICD-9-CM/ICD-10-CM Codes for MNT
/ Codes for MNT ICD (International Classification of Diseases) codes are used by physicians and medical coders to assign medical diagnoses to individual patients. It is not within the scope of practice
More informationRole of Insulin in Reduction of Body Fat / Weight Loss
Role of Insulin in Reduction of Body Fat / Weight Loss Lowering Insulin is known to help over weight persons to release weight / body fat by reducing hunger (1). You may be overweight (have greater than
More informationHigh Blood Cholesterol
National Cholesterol Education Program ATP III Guidelines At-A-Glance Quick Desk Reference 1 Step 1 2 Step 2 3 Step 3 Determine lipoprotein levels obtain complete lipoprotein profile after 9- to 12-hour
More informationBody Composition & Longevity. Ohan Karatoprak, MD, AAFP Clinical Assistant Professor, UMDNJ
Body Composition & Longevity Ohan Karatoprak, MD, AAFP Clinical Assistant Professor, UMDNJ LONGEVITY Genetic 25% Environmental Lifestyle Stress 75% BMI >30 OBESE 25-30 OVERWEIGHT 18-25 NORMAL WEIGHT 18
More informationManaging the complications of polycystic ovarian syndrome
Managing the complications of polycystic ovarian syndrome Draion M. Burch, DO Paige E. Paladino, DO Polycystic ovarian syndrome (PCOS) is the most common endocrine abnormality of reproductive-aged women.
More informationProfessional Portfolio
Professional Portfolio 8:50 AM Janet M. Myers, DNP, APRN, FNP/GNP-BC, NE-BC, ADM-BC, CDE, CLNC Table of Contents 8:46 AM Professional Development Goals References Professional Practice Evaluation Professional
More informationEndocrinology of the Female Reproductive Axis
Endocrinology of the Female Reproductive Axis girlontheriver.com Geralyn Lambert-Messerlian, PhD, FACB Professor Women and Infants Hospital Alpert Medical School at Brown University Women & Infants BROWN
More informationShira Miller, M.D. Los Angeles, CA 310-734-8864 www.shiramillermd.com. The Compounding Pharmacy of Beverly Hills Beverly Hills Public Library
Shira Miller, M.D. Los Angeles, CA 310-734-8864 The Compounding Pharmacy of Beverly Hills Beverly Hills Public Library 2 Outline What is hormone therapy? Why would healthy men and women need to think about
More informationHormonal Oral Contraceptives: An Overview By Kelsie Court. A variety of methods of contraception are currently available, giving men and
Hormonal Oral Contraceptives: An Overview By Kelsie Court A variety of methods of contraception are currently available, giving men and women plenty of options in choosing a method suitable to his or her
More informationHow do fertility drugs work?
How do fertility drugs work? Under normal circumstances, ovulation occurs once a month when a ripened egg which is ready to be fertilised is released from the ovaries. For couples who are trying to conceive,
More informationNancy S. Swayze. 2 ND YEAR RESEARCH ELECTIVE RESIDENT S JOURNAL Volume V, 2000-2001. A. Background
Efficacy Of Insulin Sensitizing Agents In Subjects With Metabolic Syndrome X And Impaired Glucose Tolerance After 6 Months Of Diet And Exercise Therapy Nancy S. Swayze A. Background Impaired glucose tolerance
More informationEpidemiology and Adverse Cardiovascular Risk Profile of Diagnosed Polycystic Ovary Syndrome
0021-972X/06/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 91(4):1357 1363 Printed in U.S.A. Copyright 2006 by The Endocrine Society doi: 10.1210/jc.2005-2430 Epidemiology and Adverse Cardiovascular
More informationDR. Trinh Thi Kim Hue
TYPE 2 DIABETES IN THE CHILD AND ADOLESCENT DR. Trinh Thi Kim Hue CONTENTS Definition Diagnosis Treatment Comorbidities and Complications Comorbidities and Complications Screening for T2D References DEFINITION
More informationYour Life Your Health Cariodmetabolic Risk Syndrome Part VII Inflammation chronic, low-grade By James L. Holly, MD The Examiner January 25, 2007
Your Life Your Health Cariodmetabolic Risk Syndrome Part VII Inflammation chronic, low-grade By James L. Holly, MD The Examiner January 25, 2007 The cardiometabolic risk syndrome is increasingly recognized
More informationHormone Replacement Therapy : The New Debate. Susan T. Hingle, M.D.
Hormone Replacement Therapy : The New Debate Susan T. Hingle, M.D. Background Hormone replacement therapy (HRT) is extensively used in the United States, especially for: *treatment of menopausal symptoms
More informationInformation About Hormonal Treatment for
Information About Hormonal Treatment for Trans Men Leighton J Seal PhD FRCP Consultant Endocrinologist, Gender Identity Clinic, West London Mental Health NHS Trust (Charing Cross) Leighton J Seal 1 Patient
More informationHôpitaux Universitaires de Genève Lipides, métabolisme des hydrates de carbonne et maladies cardio-vasculaires
Hôpitaux Universitaires de Genève Lipides, métabolisme des hydrates de carbonne et maladies cardio-vasculaires Prof. J. Philippe Effect of estrogens on glucose metabolism : Fasting Glucose, HbA1c and C-Peptide
More informationGP tool. Polycystic ovary syndrome
Polycystic ovary syndrome GP tool This resource is informed by the evidence-based guideline for the assessment and management of polycystic ovary syndrome (PCOS), authored by the PCOS Australian Alliance
More informationPCOS: Updates, Dietary Strategies And Lifestyle Treatments
: Updates, Dietary Strategies And Lifestyle Treatments Angela Grassi, MS, RDN, LDN October 3, 2015 3:30pm @nutrition Disclosure Angela Grassi, MS, RDN, LDN Board Member/Advisory Panel Consultant Employee
More informationKansas Behavioral Health Risk Bulletin
Kansas Behavioral Health Risk Bulletin Kansas Department of Health and Environment November 7, 1995 Bureau of Chronic Disease and Health Promotion Vol. 1 No. 12 Diabetes Mellitus in Kansas Diabetes mellitus
More informationCardiovascular Risk Reduction in Insulin Resistant. States. Thozhukat Sathyapalan M.B.B.S. MRCP Department of Medicine The University of Hull
Cardiovascular Risk Reduction in Insulin Resistant States Thozhukat Sathyapalan M.B.B.S. MRCP Department of Medicine The University of Hull A Thesis Submitted for the Degree of Doctor of Medicine to the
More informationHDL Cholesterol Subfractions and the Effect of Testosterone Replacement in Hypogonadism
HDL Cholesterol Subfractions and the Effect of Testosterone Replacement in Hypogonadism E. Bolu 1, A. Sonmez 1, S. Tapan 2, A. Taslipinar 1, A. Aydogdu 1, C. Meric 1, Y. Basaran 1, G. Uckaya 1, M. Serdar
More informationDiabetes and pregnancy - Antenatal care
All of our publications are available in different languages, larger print, braille (English only), audio tape or another format of your choice. Information for you Tha gach sgrìobhainn againn rim faotainn
More informationDiabetes mellitus is a chronic condition that occurs as a result of problems with the production and/or action of insulin in the body.
International Diabetes Federation Diabetes Background Information Diabetes mellitus is a chronic condition that occurs as a result of problems with the production and/or action of insulin in the body.
More informationDiabetes and Stroke. Understanding the connection between diabetes and the increased risk of stroke
Diabetes and Stroke Understanding the connection between diabetes and the increased risk of stroke Make the Connection Almost 26 million people in the U.S. roughly 8 percent of the population have diabetes.
More informationType II diabetes: How to use the new oral medications
Type II diabetes: How to use the new oral medications A TWO-PART INTERVIEW WITH NANCY J.V. BOHANNON, MD, BY DAVID B. JACK, MD Several new oral drugs have been approved for the management of type II diabetes.
More informationSex Hormones In Females And Related Disorders
Sex Hormones In Females And Related Disorders (see previous newsletter article for males) Sex Hormone production and measurement in females Follicle Stimulating Hormone () Luteinizing Hormone (), Oestradiol
More informationObesity in the United States Workforce. Findings from the National Health and Nutrition Examination Surveys (NHANES) III and 1999-2000
P F I Z E R F A C T S Obesity in the United States Workforce Findings from the National Health and Nutrition Examination Surveys (NHANES) III and 1999-2000 p p Obesity in The United States Workforce One
More information